Cargando…
Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
Remdesivir (RDV) exhibits potent antiviral activity against SARS-CoV-2 and is currently the only drug approved for the treatment of COVID-19. However, little is currently known about the potential for pre-existing resistance to RDV and the possibility of SARS-CoV-2 genetic diversification that might...
Autores principales: | Martin, Ross, Li, Jiani, Parvangada, Aiyappa, Perry, Jason, Cihlar, Tomas, Mo, Hongmei, Porter, Danielle, Svarovskaia, Evguenia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862048/ https://www.ncbi.nlm.nih.gov/pubmed/33549572 http://dx.doi.org/10.1016/j.antiviral.2021.105033 |
Ejemplares similares
-
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022) -
A web server for comparative analysis of single-cell RNA-seq data
por: Alavi, Amir, et al.
Publicado: (2018) -
THE PATHOGENESIS OF ALEUTIAN DISEASE OF MINK : I. IN VIVO VIRAL REPLICATION AND THE HOST ANTIBODY RESPONSE TO VIRAL ANTIGEN
por: Porter, David D., et al.
Publicado: (1969) -
Reply to Yan and Muller, “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”
por: Murakami, Eisuke, et al.
Publicado: (2021) -
Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
por: Stevens, Laura J., et al.
Publicado: (2022)